Renal cancer after busulphan treatment for chronic myeloid leukemia. A case report.
The incidence of secondary malignancies following chemotherapy is progressively increasing, mostly due to prolonged survival of patients treated for primary cancer. So far, only 3 cases of solid cancer following busulphan administration have been reported. We describe the case of a patient who developed a renal cancer after 4 years of busulphan treatment for chronic myeloid leukemia. Immunosuppression rather than mutagenesis seems to be responsible for the emergence of second solid cancers in patients receiving busulphan.
Iurlo
A
A
Istituto di Scienze Mediche, Padiglione Granelli, Università degli Studi, Milan, Italy.
Foa
P
P
Sala
M
M
Maiolo
A T
AT
D002066:Busulfan / Q000009:adverse effects*; D006801:Humans; D007680:Kidney Neoplasms / Q000139:chemically induced*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000139:chemically induced*
D002066:Busulfan